INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 63 filers reported holding INTELLIA THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,177,836 | -38.5% | 796,263 | -20.7% | 0.01% | -37.5% |
| Q2 2023 | $40,933,577 | +27.8% | 1,003,766 | +16.8% | 0.01% | +14.3% |
| Q1 2023 | $32,032,894 | +46.4% | 859,482 | +37.1% | 0.01% | +40.0% |
| Q4 2022 | $21,879,310 | -60.2% | 627,094 | -36.1% | 0.01% | -61.5% |
| Q3 2022 | $54,939,000 | +25.1% | 981,755 | +15.7% | 0.01% | +30.0% |
| Q2 2022 | $43,902,000 | +13.8% | 848,183 | +59.7% | 0.01% | +25.0% |
| Q1 2022 | $38,589,000 | -68.0% | 531,016 | -48.0% | 0.01% | -65.2% |
| Q4 2021 | $120,734,000 | -7.2% | 1,021,091 | +5.2% | 0.02% | -17.9% |
| Q3 2021 | $130,164,000 | -22.0% | 970,290 | -5.8% | 0.03% | -24.3% |
| Q2 2021 | $166,792,000 | +164.4% | 1,030,152 | +31.0% | 0.04% | +131.2% |
| Q1 2021 | $63,087,000 | +9.5% | 786,085 | -25.7% | 0.02% | +6.7% |
| Q4 2020 | $57,588,000 | +436.4% | 1,058,612 | +96.0% | 0.02% | +400.0% |
| Q3 2020 | $10,737,000 | +306.4% | 540,092 | +329.6% | 0.00% | +200.0% |
| Q2 2020 | $2,642,000 | +132.4% | 125,715 | +35.2% | 0.00% | – |
| Q1 2020 | $1,137,000 | -17.1% | 92,956 | -0.5% | 0.00% | – |
| Q4 2019 | $1,371,000 | -32.7% | 93,462 | -38.8% | 0.00% | -100.0% |
| Q3 2019 | $2,038,000 | -43.6% | 152,602 | -30.9% | 0.00% | 0.0% |
| Q2 2019 | $3,616,000 | +56.7% | 220,883 | +63.6% | 0.00% | 0.0% |
| Q1 2019 | $2,307,000 | +4.4% | 135,051 | -16.6% | 0.00% | 0.0% |
| Q4 2018 | $2,210,000 | -21.0% | 161,931 | +65.6% | 0.00% | 0.0% |
| Q3 2018 | $2,799,000 | +17.5% | 97,797 | +12.3% | 0.00% | 0.0% |
| Q2 2018 | $2,383,000 | +244.9% | 87,086 | +165.8% | 0.00% | – |
| Q1 2018 | $691,000 | -72.3% | 32,760 | -74.8% | 0.00% | -100.0% |
| Q4 2017 | $2,497,000 | +214.5% | 129,900 | +306.4% | 0.00% | – |
| Q3 2017 | $794,000 | +2.2% | 31,964 | -34.2% | 0.00% | – |
| Q2 2017 | $777,000 | +35.6% | 48,566 | +19.3% | 0.00% | – |
| Q1 2017 | $573,000 | -73.1% | 40,700 | -75.0% | 0.00% | -100.0% |
| Q4 2016 | $2,133,000 | -19.8% | 162,703 | +4.2% | 0.00% | 0.0% |
| Q3 2016 | $2,659,000 | -13.5% | 156,191 | +8.5% | 0.00% | 0.0% |
| Q2 2016 | $3,074,000 | – | 144,002 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 572,950 | $19,990,226 | 5.79% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $39,952,225 | 5.34% |
| MPM BioImpact LLC | 455,238 | $15,883,254 | 4.12% |
| ARK Investment Management | 9,420,782 | $328,691,084 | 2.85% |
| Atlas Venture Associates IX, LLC | 10,000 | $348,900 | 1.74% |
| Ghisallo Capital Management LLC | 250,000 | $8,722,500 | 1.55% |
| Nikko Asset Management Americas, Inc. | 2,976,002 | $103,743,430 | 1.49% |
| Prosight Management, LP | 72,116 | $2,516,127 | 1.37% |
| Rokos Capital Management LLP | 826,063 | $28,391,785 | 1.24% |
| Elmwood Wealth Management, Inc. | 67,899 | $2,368,996 | 1.18% |